Hainan Haiyao Co., Ltd.

SZSE:000566 Stock Report

Market Cap: CN¥5.6b

Hainan Haiyao Past Earnings Performance

Past criteria checks 0/6

Hainan Haiyao has been growing earnings at an average annual rate of 8.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been declining at an average rate of 12.6% per year.

Key information

8.1%

Earnings growth rate

8.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate-12.6%
Return on equity-21.7%
Net Margin-36.6%
Next Earnings Update12 Apr 2025

Recent past performance updates

Recent updates

Hainan Haiyao Co., Ltd.'s (SZSE:000566) 27% Share Price Plunge Could Signal Some Risk

Jan 10
Hainan Haiyao Co., Ltd.'s (SZSE:000566) 27% Share Price Plunge Could Signal Some Risk

What Hainan Haiyao Co., Ltd.'s (SZSE:000566) 31% Share Price Gain Is Not Telling You

Oct 25
What Hainan Haiyao Co., Ltd.'s (SZSE:000566) 31% Share Price Gain Is Not Telling You

Hainan Haiyao (SZSE:000566) Is Carrying A Fair Bit Of Debt

Oct 06
Hainan Haiyao (SZSE:000566) Is Carrying A Fair Bit Of Debt

Revenues Not Telling The Story For Hainan Haiyao Co., Ltd. (SZSE:000566)

Sep 09
Revenues Not Telling The Story For Hainan Haiyao Co., Ltd. (SZSE:000566)

Hainan Haiyao Co., Ltd.'s (SZSE:000566) Shares May Have Run Too Fast Too Soon

Jun 07
Hainan Haiyao Co., Ltd.'s (SZSE:000566) Shares May Have Run Too Fast Too Soon

Investor Optimism Abounds Hainan Haiyao Co., Ltd. (SZSE:000566) But Growth Is Lacking

Feb 26
Investor Optimism Abounds Hainan Haiyao Co., Ltd. (SZSE:000566) But Growth Is Lacking

Revenue & Expenses Breakdown

How Hainan Haiyao makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:000566 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,031-37749871
30 Jun 241,112-31639959
31 Mar 241,347-12745163
31 Dec 231,479-10649455
30 Sep 231,5575369149
30 Jun 231,6733980354
31 Mar 231,7203377550
01 Jan 231,7791182549
30 Sep 222,034-1,1261,107187
30 Jun 222,094-1,1971,187192
31 Mar 222,067-1,4221,297197
01 Jan 222,059-1,5551,304197
30 Sep 212,038-1,0971,444132
30 Jun 212,157-1,0111,480131
31 Mar 212,243-6301,404129
31 Dec 202,200-5801,456126
30 Sep 202,173-2631,439124
30 Jun 202,111-1871,402107
31 Mar 202,192-3341,557102
31 Dec 192,445-1591,51492
30 Sep 192,355141,08115
30 Jun 192,727511,04218
31 Mar 192,5701211,03819
31 Dec 182,4721201,02619
30 Sep 182,6161401,11445
30 Jun 182,2141231,00043
31 Mar 182,0759374933
31 Dec 171,8258766131
30 Sep 171,7531726024
30 Jun 171,5111645720
31 Mar 171,5411725770
31 Dec 161,5091655540
30 Sep 161,4571324240
30 Jun 161,5941964230
31 Mar 161,6491974280
31 Dec 151,6441954230
30 Sep 151,4842263590
30 Jun 151,4281823630
31 Mar 151,3711783520
31 Dec 141,3431633310
30 Sep 141,2641783220
30 Jun 141,1851293170
31 Mar 141,018963150

Quality Earnings: 000566 is currently unprofitable.

Growing Profit Margin: 000566 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 000566 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.1% per year.

Accelerating Growth: Unable to compare 000566's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 000566 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).

Return on Equity

High ROE: 000566 has a negative Return on Equity (-21.72%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 07:10
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hainan Haiyao Co., Ltd. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhouyu DengGuosen Securities Co., Ltd.
Wenxin YuHaitong Securities Co., Ltd.
Ye Hui YangHuatai Research